Background: The incidence of chronic myeloid leukemia (CML) increases with age, but it is unclear how the characteristics of the disease vary with age. In children, where CML is very rare, it presents with more aggressive features, including huge splenomegaly, higher cell count and higher blast cell percentage. Patients and methods: To investigate if after childhood the disease maintains or loses these characteristics of aggressiveness, we analyzed 2784 adult patients, at least 18 years old, registered by GIMEMA CMLWP over a 40-year period. Results: Young adults (YAs: 18-29 years old) significantly differed from adults (30-59 years old) and elderly patients (at least 60 years old) particularly for the frequency of splenomegaly (71%, 63% and...
To assess the effect of age on response and compliance to treatment in patients with chronic myeloid...
The median age of chronic myeloid leukemia (CML) patients is similar to 60 years, and age is still c...
AimsWe aimed to investigate whether older age leads to limitations in the starting dose of imatinib ...
Background: The incidence of chronic myeloid leukemia (CML) increases with age, but it is unclear ho...
The incidence of chronic myeloid leukemia (CML) increases with age, but it is unclear how the charac...
BACKGROUND: The incidence of chronic myeloid leukemia (CML) increases with age, but it is unclear ho...
Background: The incidence of chronic myeloid leukemia (CML) increases with age, but it is unclear ho...
To assess the effect of age on response and compliance to treatment in patients with chronic myeloid...
To assess the effect of age on response and compliance to treatment in patients with chronic myeloid...
OBJECTIVES: To evaluate differences in clinical results according to age among patients with chroni...
Aims: We aimed to investigate whether older age leads to limitations in the starting dose of imatini...
In older patients with chronic myelomonocytic leukaemia (CMML) and limited life expectancy due to ag...
AIMS: We aimed to investigate whether older age leads to limitations in the starting dose of imatini...
none18noTo assess the effect of age on response and compliance to treatment in patients with chronic...
Chronic myeloid leukemia (CML) is a disease of the hematopoietic stem cell characterized by a median...
To assess the effect of age on response and compliance to treatment in patients with chronic myeloid...
The median age of chronic myeloid leukemia (CML) patients is similar to 60 years, and age is still c...
AimsWe aimed to investigate whether older age leads to limitations in the starting dose of imatinib ...
Background: The incidence of chronic myeloid leukemia (CML) increases with age, but it is unclear ho...
The incidence of chronic myeloid leukemia (CML) increases with age, but it is unclear how the charac...
BACKGROUND: The incidence of chronic myeloid leukemia (CML) increases with age, but it is unclear ho...
Background: The incidence of chronic myeloid leukemia (CML) increases with age, but it is unclear ho...
To assess the effect of age on response and compliance to treatment in patients with chronic myeloid...
To assess the effect of age on response and compliance to treatment in patients with chronic myeloid...
OBJECTIVES: To evaluate differences in clinical results according to age among patients with chroni...
Aims: We aimed to investigate whether older age leads to limitations in the starting dose of imatini...
In older patients with chronic myelomonocytic leukaemia (CMML) and limited life expectancy due to ag...
AIMS: We aimed to investigate whether older age leads to limitations in the starting dose of imatini...
none18noTo assess the effect of age on response and compliance to treatment in patients with chronic...
Chronic myeloid leukemia (CML) is a disease of the hematopoietic stem cell characterized by a median...
To assess the effect of age on response and compliance to treatment in patients with chronic myeloid...
The median age of chronic myeloid leukemia (CML) patients is similar to 60 years, and age is still c...
AimsWe aimed to investigate whether older age leads to limitations in the starting dose of imatinib ...